Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Selective serotonin reuptake inhibitors are still harmful and ineffective. Responses to the comments by Hieronymus et al

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Differential plastic changes in synthesis and binding in the mouse somatostatin system after electroconvulsive stimulation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Psychotic Depression Assessment Scale (PDAS) in measurement-based care of patients with psychotic depression

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Anaesthesia for electroconvulsive therapy - new tricks for old drugs: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  1. Characteristics influencing expected cognitive performance during hypoglycaemia in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Assessment and treatment of cognitive impairments in patients with affective disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Erythropoietin (EPO) has been suggested to improve metabolism and also cognition, but human studies are scarce. This randomised controlled trial aimed to investigate whether EPO treatment influences body composition and fat and glycated haemoglobin (HbA1c) and fasting glucose, and whether these changes would be associated with previous observed cognitive benefits of EPO.

METHOD: In total, 84 non-obese patients with treatment-resistant unipolar depression or bipolar disorder in remission were randomised to 8 weekly EPO (40,000 IU) or saline (NaCl 0.9%) infusions in a double-blind, parallel-group design. Patients underwent dual X-ray absorptiometry scans at baseline and week 14 (6 weeks after treatment completion). Cognitive measures were assessed and fasting levels of cholesterol, lipoprotein fractions, triacylglycerides, glucose and HbA1c were obtained at baseline, week 9 and follow-up week 14.

RESULTS: In total, 79 patients had complete pre- and post-treatment data (EPO: N=40, saline: N=39). EPO had no cumulative effect on body composition and markers of fat metabolism. The EPO-treated group exhibited significantly lower HbA1c levels after 8 weeks treatment [F(1, 80)=8.51, p=0.005], however, 6 weeks after treatment termination a significantly higher fasting glucose levels [F(1, 79)=5.85, p=0.02] and HbA1c levels [F(1, 79)=5.85, p=0.02] were seen. The latter increase in HbA1c was further significantly correlated with a better cognitive outcome on verbal memory (r=0.25, p=0.03).

CONCLUSION: Repeated EPO infusions had no cumulative effect on body composition in this cohort of patients with affective disorders, however, EPO modulated HbA1c and fasting glucose and this was associated with patients' improvement of verbal memory.

Original languageEnglish
JournalActa Neuropsychiatrica
Pages (from-to)1-8
Number of pages8
ISSN1601-5215
DOIs
Publication statusPublished - 8 Jun 2018

ID: 55377286